Relacorilant added to nab-paclitaxel prolongs progression-free survival in platinum-resistant ovarian cancer
The ROSELLA trial highlights the efficacy and tolerability of the combination even in patients with a poorer prognosis
An analysis reveals distinct patterns of expression of antibody–drug conjugate targets in high-grade serous ovarian cancer
A small Japanese study provides useful insights on determining the role of these agents in cancer care, but studies in larger, more diverse populations are needed
Talazoparib plus axitinib show some signs of efficacy in heavily pretreated cancers
Early-phase findings report manageable toxicity when combining the PARP inhibitor with the anti-angiogenesis inhibitor in two cohorts of patients with ovarian and castration-resistant prostate tumours
Clinical benefits shown with pembrolizumab plus chemotherapy regardless bevacizumab use in advanced or recurrent cervical cancer
Findings are from an exploratory subgroup analysis of the KEYNOTE-826
Three new Pan-Asian-adapted guidelines at ESMO Asia Congress
The latest tumour types covered in the ESMO PAGAs are biliary tract cancers, oncogene-addicted metastatic non-small cell lung cancer and epithelial ovarian cancer
Pembrolizumab plus concurrent chemoradiotherapy extends survival in locally advanced cervical cancer
New study findings support this treatment strategy as a new standard of care for patients with high-risk, locally advanced cervical cancer
Five-year PFS results show advantage for niraparib maintenance in patients with advanced ovarian cancer, with no OS benefit
Patients with homologous-recombination-deficient advanced ovarian cancer alive at 5 years were twice as likely to be progression free with niraparib than placebo, although no long-term overall survival benefit was reported
Towards a brighter future for gynaecological cancers
Improvements in the understanding of molecular mechanisms, together with a greater focus on prevention, are key elements to countering gynaecological malignancies
Disappointing early results for niraparib plus dostarlimab in the treatment of relapsed endometrial or ovarian carcinosarcomas
The phase II part of the ROCSAN trial failed to meet its primary endpoint but there may be potential for benefit based on efficacy and safety data with the combination
PD-1 inhibition plus chemoradiotherapy is effective across ethnicities in locally advanced cervical cancer
However, studies highlight cost as an obstacle to widespread accessibility in some countries